Last Updated: November 13, 2026

Chartwell Rx Company Profile

« Back to Dashboard


What is the competitive landscape for CHARTWELL RX

CHARTWELL RX has four hundred and ninety-seven approved drugs.

There are two tentative approvals on CHARTWELL RX drugs.

Summary for Chartwell Rx
US Patents:0
Tradenames:348
Ingredients:327
NDAs:497

Drugs and US Patents for Chartwell Rx

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chartwell Rx TAZORAC tazarotene CREAM;TOPICAL 021184-002 Sep 29, 2000 AB RX Yes Yes ⤷  Start Trial ⤷  Start Trial
Chartwell Rx MOBAN molindone hydrochloride CAPSULE;ORAL 017111-002 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Start Trial ⤷  Start Trial
Chartwell Rx AMOXICILLIN amoxicillin FOR SUSPENSION;ORAL 062059-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial
Chartwell Rx PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE amitriptyline hydrochloride; perphenazine TABLET;ORAL 073007-001 Oct 17, 1991 DISCN No No ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Chartwell Rx

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chartwell Rx TAZORAC tazarotene GEL;TOPICAL 020600-002 Jun 13, 1997 5,089,509 ⤷  Start Trial
Chartwell Rx AVAGE tazarotene CREAM;TOPICAL 021184-003 Sep 30, 2002 5,089,509 ⤷  Start Trial
Chartwell Rx TAZORAC tazarotene GEL;TOPICAL 020600-001 Jun 13, 1997 5,089,509 ⤷  Start Trial
Chartwell Rx MOBAN molindone hydrochloride TABLET;ORAL 017111-006 Approved Prior to Jan 1, 1982 3,491,093 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.